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Abstract
Background: Adiponectin has insulin-sensitizing and anti-atherosclerotic effects, partly mediated through its action
on monocytes. We aimed to determine adiponectin levels and expression of its receptors (AdipoR1 and AdipoR2)
in peripheral monocytes from overweight and obese patients with coronary artery disease (CAD).
Methods: Fifty-five overweight/obese patients, suspected for CAD, underwent coronary angiography: 31 were
classified as CAD patients (stenosis ≥ 50% in at least one main vessel) and 24 as nonCAD. Quantitative RT-PCR and
flow cytometry were used for determining mRNA and protein surface expression of adiponectin receptors in
peripheral monocytes. A high sensitivity multiplex assay (xMAP technology) was used for the determination of
plasma adiponectin and interleukin-10 (IL-10) secreted levels.
Results: Plasma adiponectin levels were decreased in CAD compared to nonCAD patients (10.9 ± 3.1 vs. 13.8 ±
5.8 μg/ml respectively, p = 0.033). In multivariable analysis, Matsuda index was the sole independent determinant
of adiponectin levels. AdipoR1 and AdipoR2 protein levels were decreased in monocytes from CAD compared to
nonCAD patients (59.5 ± 24.9 vs. 80 ± 46 and 70.7 ± 39 vs. 95.6 ± 47.8 Mean Fluorescence Intensity Arbitrary Units
respectively, p < 0.05). No significant differences were observed concerning the mRNA levels of the adiponectin
receptors between CAD and nonCAD patients. AdipoR2 protein levels were positively correlated with plasma
adiponectin and Matsuda index (r = 0.36 and 0.31 respectively, p < 0.05 for both). Furthermore, basal as well as
adiponectin-induced IL-10 release was reduced in monocyte-derived macrophages from CAD compared to
nonCAD subjects.
Conclusions: Overweight patients with CAD compared to those without CAD, had decreased plasma adiponectin
levels, as well as decreased surface expression of adiponectin receptors in peripheral monocytes. This fact together
with the reduced adiponectin-induced IL-10 secretion from CAD macrophages could explain to a certain extent, an
impaired atheroprotective action of adiponectin.
Background
Cardiovascular disease (CVD) is a leading cause of mor-
tality worldwide accounting for 30% of total global
deaths and the number one leading cause of deaths in
developing countries. Various studies have demonstrated
the association of obesity and insulin resistance with
cardiovascular risk. It has been recognized that inflam-
matory mechanisms play a pivotal role in initiation,
maintenance and progress of CVD and that the associa-
tion of CVD with obesity is mediated through the adi-
pose tissue secretory activities.
Adiponectin, an adipose tissue secreted protein, has
been well recognized to exhibit insulin-sensitizing, anti-
inflammatory and anti-atherosclerotic properties, which
are mediated through its receptors, AdipoR1 and
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expressed in most organs as well as in human peripheral
monocytes, and in monocyte-derived macrophages [2-5].
In these cells, adiponectin has been shown to modulate
their inflammatory activity and most importantly to
inhibit their transformation to foam cells, a hallmark of
atherosclerosis [6-10]. More specifically, adiponectin
induces the anti-inflammatory cytokine IL-10 in human
monocytes and macrophages [5,6,11], while it suppresses
the LPS-stimulated release of IL-6 in porcine macro-
phages [8]. Furthermore, adiponectin-induced secretion
of IL-6 and IL-8 is reduced in monocytes from patients
with type 1 or type 2 diabetes [5,12]. This fact may have
significant implications in terms of atherosclerotic pro-
cesses, since these cells play a pivotal role in inflamma-
tion and atherosclerosis [13].
Adiponectin levels are known to be decreased in
patients with obesity, type 2 diabetes and coronary
artery disease (CAD) [14-17]. However, in recent stu-
dies, adiponectin was shown to be associated with an
adverse outcome in patients with CAD, challenging the
emerging evidence for its role [18-21]. In addition,
alterations at the level of adiponectin receptors expres-
sion have been reported but with inconclusive results
showing upregulation or downregulation in the presence
of insulin resistance [5,22-28]. Recently, a lower abun-
dance of adiponectin receptors was found in monocytes
from overweight/obese patients with type 2 diabetes [5].
However, the expression levels of adiponectin receptors
have not been examined in CAD.
T h ea i mo ft h i ss t u d yw a st oe x a m i n ew h e t h e rt h e
relative mRNA and protein (surface) expression of Adi-
poR1 and AdipoR2 in human peripheral monocytes is
altered in overweight/obese patients with CAD, and
whether this might relate to their circulating adiponectin
levels and to indices of insulin resistance and
atherosclerosis.
Methods
Subjects and investigation
Our study included patients with Body Mass Index
(BMI) above 25 Kg/m
2 who underwent elective coronary
angiography for the investigation of the existence of
chronic stable CAD. Patients with a 50% or greater dia-
meter stenosis in at least one major coronary artery
were considered as CAD positive patients. The exclusion
criteria were: unstable angina or acute myocardial
infarction, unstable condition including infections, heart
failure, malignancies, renal disease (creatinin level >
1.5 mg/dl). All patients underwent intima-media thick-
ness (IMT) assessment in 2 paired segments of both
common carotids, as well as in carotid bulbs using B-
mode ultrasound imaging. IMT was measured using an
automatically trading software (Vivid 7 GE Horton,
Norway). The research conducted in this paper has been
carried out in accordance with the Declaration of
Helsinki (2000) of the World Medical Association and
the study protocol was approved by the Scientific and
Ethics Committee of “Attikon” University General Hos-
pital. All patients gave their written informed consent.
Two to three weeks after their discharge from the Car-
diology Department, patients were subjected to a 2-hour
oral glucose (75gr) tolerance test (OGTT) for the assess-
ment of their insulin resistance status. All subjects were
informed to halt their medication at least one day before
the OGTT, as necessary. Insulin resistance was calculated
by the homeostasis model assessment index (HOMA-IR)
as [fasting insulin (μU/mL) × fasting glucose (mmol/L)]/
22.5 [29]. Insulin sensitivity was calculated by the Mat-
suda index as [10.000/square root of (fasting glucose ×
fasting insulin) × (mean glucose during OGTT × mean
insulin during OGTT)] [30]. At the beginning of the
OGTT, fasting blood was drawn and plasma was kept at
-80°C for measurement of adiponectin levels. Fasting tri-
glycerides, total and HDL- cholesterol were determined
by an ILAB analyser (Instrumentation Laboratory SpA,
Italy). Plasma glucose levels at fasting and during the
OGTT, were analyzed on a Falcor 300 Chemical Analyser
(Menarini Diagnostics, Italy), while plasma insulin levels
were measured by IRMA (INSI-CTK, DiaSorin, Italy), in
all individuals.
BMI was calculated as the ratio of body weight (Kg)
per height (m
2). Waist and hip circumference, weight
and height were also measured in all individuals. Fifty-
five patients, aged between 41 and 75 years, were eligi-
b l et ob ei n c l u d e di nt h es t u d ya m o n g7 1s u b j e c t s
screened. All patients were of a stable weight and had
been on a normal isocaloric diet with normal physical
activity, not participating in any specific exercise pro-
gram. Information about use of medication, such as
antihyperlipidemic, antidiabetic and antihypertensive
medication was also collected. None of the patients
were taking thiazolidinedione medication.
Study of adiponectin receptors surface (protein)
expression with flow cytometry
The mononuclear cell fraction was isolated from periph-
eral blood and the surface adiponectin receptors, Adi-
poR1 and AdipoR2, were determined after staining the
cells with suitable antibodies. More specifically, the anti-
bodies used were rabbit anti-mouse AdipoR1 and rabbit
anti-mouse AdipoR2 (Alpha Diagnostic International,
San Antonio, USA), each corresponding to the extracel-
lular carboxy-terminus domain of the respective recep-
tor. Since the antibodies were not fluorochrome
conjugated, they were labelled with the Zenon™ Alexa
Fluor
® 488 Rabbit IgG labelling kit (Invitrogen, Carls-
bad, CA, USA). Cells were incubated for 30 min with
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® 488-conjugated immunoglobulin in a ratio
1×1 0
6 cells μg
-1 of immunoglobulin under mild
constant shaking. The monocyte fraction was simulta-
neously stained with anti-CD14-PE monoclonal antibody
( B DB i o s c i e n c e s ,S a nJ o s e ,C A ,U S A ) .A f t e ri n c u b a t i o n
with the antisera, cells were fixed with 0.1% (w/v) paraf-
ormaldehyde. A histogram of log green fluorescence of
each adiponectin receptor was used for the determina-
tion of the mean fluorescence intensity of each sample
(Figure 1).
The specificity of the antibodies used was evaluated by
staining cells with isotype controls suitable for each
antisera and the blockage of Fc-receptors prior to stain-
ing [31].
Two-colour flow cytometric analysis was performed
on a BD FACSCalibur 4 colour flow cytometer (BD
Biosciences) as previously described [31]. Data acquisi-
tion and analysis were performed using the BD CELL
Quest Pro software (BD Biosciences). Results are
expressed in mean fluorescence intensity arbitrary units
(MFI AU).
Isolation of peripheral monocytes
Monocytes were isolated from mononuclear cells using
a Magnetic Cell-Sorting technique with CD14 Human
MicroBeads (Miltenyi Biotec, Gladbach, Germany). The
exact number of cells was determined cytometrically
with Flow-Count™ Flurospheres (Beckman-Coulter,
Miami, USA). The purity of the magnetically isolated
CD14
+ monocytes was determined after staining of the
cells with a CD14 PE-CD45 FITC antibody (BD Bios-
ciences, USA)
RNA preparation
Total RNA was extracted from CD14
+ monocytes using
the Tripure Isolation Reagent (Roche Diagnostics
GmbH, Mannheim, Germany), and the integrity of RNA
samples was determined on ethidium bromide-agarose
gels and spectrophotometrically. For the removal of any
residual DNA contamination, RNA samples were pre-
incubated with RQ1 RNase-free DNase (Promega, Madi-
son, WI, USA) before the reverse transcription reaction.
Reverse transcription of 1 μg of total RNA was per-
formed in all samples with the Transcriptor First Strand
cDNA Synthesis Kit using random hexamer primers,
according to the manufacturer’si n s t r u c t i o n s( R o c h e
Diagnostics GmbH, Mannheim, Germany).
Relative real-time PCR quantification of adiponectin
receptors mRNA expression
A quantitative real-time PCR using fluorescently labeled
hybridization probes was developed for detecting relative
AdipoR1 and AdipoR2 mRNA levels in human CD14
+
monocytes, in a spectrofluorometric thermal cycler
(LightCycler, ROCHE, Manheim, Germany) as pre-
viously described [32].
Hybridization specific primers and fluorescently
labelled hybridization specific probes for all genes were
designed and manufactured by the TIM-MOLBIOL
(Berlin, Germany). Primers were chosen to lie between
exons whenever possible and the analysis was performed
with the program OLIGO 6.0 (Molecular Biology
Insights, Cascade, USA). The specific reaction condi-
tions for each set of genes (primer concentration,
annealing temperature, magnesium chloride) were opti-
mized using first the SYBR Green fluorescent dye
(LightCycler
® FastStart DNA Master SYBR Green I,
Roche Diagnostics). Hybridization primers (sense and a-
sense, respectively) for the targets (AdipoR1, AdipoR2)
and reference genes (b-actin) were as follows: for Adi-
poR1: 5’-TTTGACATATGGTTCCAGTCTCA-3’ and
5’- GACTCTTCCTCTCACTTCAGCAA-3’,f o rA d i -
poR2: 5’-TGACATCTGGTTTCACTCTCATCAG-3’ and
5’-GTCATAGTCCCTGGAGACTGGT-3’,f o rb-actin:
5’-CTTCTACAATGAGCTGCGTGTG-3’ and 5’-GTGA
GGATCTTCATGAGGTAGTCAGTC-3’. Hybridization
probes (FL- and LC Red640-probes, respectively) for the
targets (AdipoR1, AdipoR2) and reference genes
(b-actin) were as follows: for AdipoR1: 5’-CCGTAACG-
GAATTCCTGAAGGTTGGAGAC-3’ and 5’-CCATA-
GAAGTGGACAAAGGCTGCTGCC-3’, for AdipoR2:
5’-CCTGGAGGTTTGAGACACCATGGA AG-3’ and
5’-GAACAAAAGCTCCAGCAACCACAAA GATA-3’,
for b-actin: 5’- GGTATGCCCTCCCCCA TGCC-3’ and
5’- TCCTGCGTCTGGACCTGGCTG-3’.
Relative quantification is the method that determines
the changes in steady-state mRNA levels of a gene
A B
C
Figure 1 Flow cytometric analysis of adiponectin receptors in
isolated monocytes. (A) Dot plot presentation of isolated
mononuclear cells. Cells subpopulations were distinguished by
granularity (side scatter) versus staining with CD14-PE monoclonal
antibody. Monocytes (CD14-PE
+) were gated (R). (B) Analysis of
Adipo-R2 log fluorescence of the gated monocytes. (C) Dot plot of
the Adipo-R2 expression versus CD14-PE. The upper right quadrant
includes the cells showing positive expression for both adipoR2 and
CD14 antibodies (green colour).
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the levels of an internal reference control gene, usually a
housekeeping gene. Standard curves describing the PCR
efficiencies of the target (AdipoR1 and AdipoR2) and
the reference genes (b-actin) were created from a dilu-
tion series of the calibrator cDNA (HL60 cDNA induced
with phorbol myristyl acetate -PMA-), using the Second
Derivative Maximum Method with the Arithmetic base-
line adjustment for the determination of the various
c r o s s i n gp o i n t s .T oq u a n t i f yt h er e l a t i v ee x p r e s s i o n
levels of Adipo-Rs mRNA in the various samples, we
run the target and the reference gene of each sample,
along with the calibrator cDNA, and the final results
were calculated using the LightCycler Relative Quantifi-
cation 1.0.1 Software (ROCHE, Manheim, Germany).
Samples were run in duplicates or triplicates and results
are expressed in arbitrary units (AU). The results from
different PCR runs were run randomly in ethidium bro-
mide stained agarose gels and photographed in a Gel-
Doc-It 300 Imaging System (UVP, Cambridge, UK).
Cell culture
Mononuclear cells from peripheral blood were resus-
pended in RPMI-1640 medium (GIBCO-INVITROGEN
Corp, Carlsbad, CA, USA), supplemented with 10%
human type AB male serum (SIGMA-ALDRICH Corp,
St. Louis, MO, USA) and 1% Penicillin/streptomycin
(5000 IU/ml-5000 μgr/ml) (GIBCO-INVITROGEN
Corp, Carlsbad, CA, U.S.A) and incubated in 10 cm cell
culture dishes for 1 hour. Non-adherent cells were
removed and the remaining adherent cells were col-
lected, counted and aliquoted in a 24-well plate at a
density of 2-3 × 10
6 cells/well. Cells were left in a 37°C
CO2 incubator for 7 days and the medium was changed
every two days. After that period, human monocyte-
derived macrophages were incubated with human
recombinant full-length adiponectin (30 μg/ml) (R&D
Systems, Minneapolis, MN, USA) for further 48 hours.
At the end of the incubation period, cell supernatants
were collected, aliquoted and kept at -80°C for measure-
ment of released IL-10.
Immunoassays
Circulating levels of adiponectin were measured in the
plasma of all subjects, using a high sensitivity multiplex
assay (xMAP technology) and the fluorescently labeled
microsphere beads (HCVD1-67AK Lincoplex kit, Milli-
pore Corp., MA, USA), in a LUMINEX 200 instrument
(Luminex Corp., USA). Sensitivity of the assay was 56.0
pg/ml, intra-assay and inter-assay coefficients of varia-
tion were 9.2% and 15.9%, respectively. All samples were
diluted 1:100 and measured in duplicate. Samples that
could not be detected, were measured again using a
higher dilution.
IL-10 secreted levels were measured in the superna-
tants from human monocyte-derived macrophages using
a MILLIPLEX MAP kit (MPXHCYTO-60 K, Millipore
Corp., MA, USA), in a LUMINEX 200 instrument
(Luminex Corp., USA). Sensitivity of the assay was
0.5 pg/ml and intra-assay and inter-assay coefficients of
variation were 5.2% and 9.5%.
Statistical analysis
Statistical analysis was performed using the SPSS version
14.0.1 software (Chicago, Ill, USA). Data are expressed
as mean ± SD. Variables that were not normally distrib-
uted (AdipoR1 and AdipoR2 mRNA levels, adiponectin,
HOMA index) were logarithmically transformed. Chi
square was implemented for categorical variables. Para-
metric statistical analyses (Pearson’s correlation test,
unpaired or paired t-test) were applied where appropri-
ate. Multivariate regression analysis (results as mean ±
SE), as well as analysis of covariance (ANCOVA) were
also performed if any adjustments were necessary. A p-
value of less than 0.05 was considered statistically
significant.
Results
Patients’ characteristics
The clinical and metabolic characteristics, as well as
the therapeutic regimen of the patients included in the
study are presented in Table 1. From the 55 subjects,
46 were males and no differences were observed in
BMI between males and females (28.9 ± 2.6 vs. 28.2 ±
2.1 respectively, p = 0.44). Overweight/obese patients
with CAD were more likely to be males, while no dif-
ferences were observed with regard to age, BMI, lipid
profile, systolic and diastolic blood pressure compared
to similar weight patients without CAD. Patients with
CAD had higher values of waist to hip ratio, higher
carotid IMT values, decreased levels of plasma adipo-
nectin and decreased insulin sensitivity as assessed by
Matsuda index (Table 1). Moreover, the decrease
in plasma adiponectin levels remained significant after
adjustment for gender (p = 0.046) and BMI (p =
0.025).
Plasma adiponectin levels and associations
Circulating plasma adiponectin levels were positively
associated with Matsuda index and HDL-cholesterol
levels, overall (r = 0.315, p = 0.022 and r = 0.29 p =
0.048, respectively, Table 2). In stepwise multivariable
analysis with age, gender, waist to hip ratio, the pre-
sence of CAD, Matsuda index and the various medica-
tions as independent variables, insulin sensitivity
(Matsuda index) (beta ± SE: 0.43 ± 0.02, p = 0.024) was
the sole independent determinant of adiponectin levels
(R
2 = 0.10).
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Patients without CAD
(n = 24)
Patients with CAD
(n = 31)
p value
Anthropometric characteristics
Males (%) 16 (67) 30 (97) 0.009
Age (years) 57.6 ± 7.7 60.2 ± 8.5 0.249
BMI (Kg/m
2) 28.5 ± 2.5 29.1 ± 2.6 0.340
Waist to hip ratio 0.93 ± 0.06 1 ± 0.06 <0.001
Metabolic characteristics
LDL-cholesterol (mmol/L) 3.41 ± 0.88 3.12 ± 0.72 0.260
HDL-cholesterol (mmol/L) 1.27 ± 0.28 1.11 ± 0.25 0.078
Triglycerides (mmol/L) 1.31 ± 0.45 1.59 ± 0.15 0.231
Systolic BP (mmHg) 123.5 ± 16.4 128.4 ± 12.3 0.228
Diastolic BP (mmHg) 76.5 ± 9.8 79.6 ± 6.8 0.176
Adiponectin (μg/ml) 13.8 ± 5.8 10.9 ± 3.1 0.033*
Indices
HOMA index 3.52 ± 1.84 5.17 ± 4.78 0.102*
Matsuda index 2.90 ± 1.14 2.28 ± 1.0 0.041
Common carotid IMT (mm) 0.86 ± 0.25 1.10 ± 0.30 0.004
Carotid bulb IMT (mm) 1.14 ± 0.75 1.49 ± 0.48 0.062
Drug use
Statins (%) 9 (38) 25 (81) 0.003
Antiplatelets (%) 8 (33) 27 (87) <0.001
ACE inhibitor, AR antagonists (%) 9 (38) 25 (81) 0.003
Nitrates (%) 3 (13) 13 (42) 0.037
b-blockers (%) 5 (21) 21 (68) 0.001
Calcium channel blockers (%) 3 (13) 7 (23) 0.543
Sulfonylureas (%) 0 (0) 4 (13) 0.192
Metformin (%) 1 (4) 5 (16) 0.329
BMI: Body Mass Index; LDL: Low density lipoprotein; HDL: High density lipoprotein; BP: Blood Pressure; IMT: Intima media thickness; ACE: Angiotensin Converting
Enzyme; AR: Angiotensin Receptor.
* comparisons in logarithmic scale.
Table 2 Bivariate correlations of adiponectin and its receptors with the studied variables
AdipoR1
protein
AdipoR2
protein
logAdipoR1
mRNA
logAdipoR2
mRNA
logAdiponectin
AdipoR2 protein 0.757**
logAdipoR1 mRNA -0.141 -0.258
logAdipoR2 mRNA 0.003 0.039 0.52**
logAdiponectin 0.245 0.359** -0.156 -0.080
Age (years) -0.079 -0.081 0.225 0.236 0.098
LDL-C (mmol/L) 0.045 0.025 -0.063 -0.307 0.058
HDL-C (mmol/L) 0.269 0.153 0.052 0.025 0.29*
Triglycerides (mmol/L) -0.179 -0.145 0.131 0.325* -0.133
Systolic BP (mmHg) -0.132 -0.010 0.068 0.303* -0.006
Diastolic BP (mmHg) -0.061 0.040 -0.028 -0.018 -0.124
logHOMA index -0.140 -0.263 0.270 0.146 -0.152
Matsuda index 0.221 0.310* -0.342 -0.035 0.315*
Common carotid IMT (mm) -0.162 -0.124 0.103 0.189 0.075
Carotid bulb IMT (mm) -0.082 0.02 -0.123 0.254 0.122
LDL: Low density lipoprotein; HDL: High density lipoprotein; BP: Blood Pressure; IMT: Intima media thickness * p < 0.05, ** p < 0.01.
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Both AdipoR1 and AdipoR2 were found to be expressed
in peripheral monocytes at mRNA and protein surface
level. While AdipoR1 mRNA was more abundant com-
pared with AdipoR2 mRNA in monocytes (3.5 ± 3.2 vs.
1 ± 0.9 AU, p < 0.001), the opposite was true for the
protein surface expression levels (68.2 ± 36.5 vs. 81.3 ±
44.3 MFI AU respectively, p = 0.002). Overweight/obese
patients with CAD, apart from the decreased plasma
adiponectin levels, had decreased AdipoR1 and AdipoR2
protein surface levels compared to patients without
C A D ,w h i l et h e yd i dn o ts h o wa n yd i f f e r e n c ew i t h
respect to the levels of AdipoR1 and AdipoR2 mRNA
( F i g u r e2 Aa n d2 B ) .T h ed i f f e r e n c ei np r o t e i ns u r f a c e
expression of AdipoR1 and AdipoR2 with respect to the
presence of CAD remained significant for AdipoR1 after
adjustment for gender difference (p = 0.033) but was
attenuated for AdipoR2 (p = 0.074). However, after
adjustment for Matsuda index the difference in protein
surface expression was attenuated for both AdipoR1 and
AdipoR2 (p = 0.13 and 0.08 respectively).
Moreover, a robust positive correlation was observed
between AdipoR1 and AdipoR2 mRNA, as well as
between AdipoR1 and AdipoR2 surface levels (Figure 3).
AdipoR1 mRNA levels were inversely correlated with
Matsuda index, whereas AdipoR2 mRNA levels were cor-
related with systolic blood pressure and triglycerides
(Table 2). AdipoR2 protein surface levels were associated
with plasma adiponectin levels and Matsuda index
(Figure 4) and retained this association with plasma adi-
ponectin levels (beta ± SE: 107.58 ± 40.7, p = 0.011) and
Matsuda index (beta ± SE: 13.21 ± 6.46, p = 0.047) in
multiple regression analysis independent of age, gender
and waist to hip ratio. When the latter analysis was con-
fined to the subgroup of CAD patients, AdipoR2 protein
surface levels were also correlated with plasma adiponec-
tin levels (beta ± SE: 110.02 ± 48.89, p = 0.034) and Mat-
suda index (beta ± SE: 25.603 ± 6.060, p < 0.001)
independent of age, gender and waist to hip ratio.
Although no associations were revealed overall,
between common carotid or bulb IMT with adiponectin
receptors mRNA or protein surface levels (Table 2), in
subgroup analyses, a positive correlation was found
between AdipoR2 protein levels and carotid bulb IMT
in CAD patients (r = 0.428, p = 0.026).
Adiponectin-induced Interleukin-10 production
In monocyte-derived macrophages from overweight/
obese CAD patients, basal IL-10 secreted levels were
decreased compared to nonCAD subjects (5.0 ± 7.3 pg/
ml vs. 20.3 ± 12.2 pg/ml, p = 0.002) (Figure 5). More-
over, adiponectin treatment of CAD and nonCAD cells
significantly induced IL-10 (13.8-fold, p = 0.005 and 19-
f o l d ,p<0 . 0 0 1 ,r e s p e c t i v e l y ) ,a l t h o u g ha d i p o n e c t i n -
induced IL-10 release was significantly lower in
CAD patients compared to nonCAD subjects (69.2 ±
80.1 pg/ml vs. 386.3 ± 488.2 pg/ml, p = 0.047) (Figure 5).
Discussion
Plasma adiponectin levels and associations
Adiponectin is an adipocyte derived protein that exerts
anti-inflammatory and anti-atherogenic effects in part
by modulating monocyte and macrophage functions.
More specifically, adiponectin may prime human mono-
cytes toward the anti-inflammatory M2 phenotype, inhi-
bit the secretion of inflammatory cytokines from
monocyte-derived macrophages, prevent monocyte
adhesion to endothelial cells and suppress macrophage-
to-foam cell transformation [6-10]. In addition, the new
adiponectin paralogous protein CTRP-3 has been
reported to play a significant role by inhibiting LPS-
induced IL-6 and TNF release from human monocytes
[33]. Adiponectin receptors have been detected in
human monocytes and macrophages [3,4] and recently
it was found that variants of the AdipoR2 could be a
determinant for atherosclerosis independent of insulin
resistance [34]. However the significance of the adipo-
nectin receptors in mediating its beneficial effects in
states of CAD has not been examined.
In this study, adiponectin levels were found to be mar-
ginally decreased in overweight patients with CAD com-
pared to similar weight control individuals. Although
this finding could be expected according to the evidence
from previous studies [14], this view is questioned.
A couple of studies failed to reveal a relationship of adi-
ponectin levels with early [35] or advanced atherosclero-
sis [36]. In other studies, adiponectin levels were found
to be associated with an adverse outcome in patients
with CAD [18-21]. In addition, Rizza et al. reported that
adiponectin levels in patients with CAD were not corre-
lated with the severity of CAD, but inversely associated
with defects of glucose metabolism [37]. Interestingly, in
our study, when adjusting for several factors, adiponec-
tin levels did not differ with respect to the presence of
CAD, but were independently associated with Matsuda
index. Furthermore, the positive association of plasma
adiponectin with HDL-C levels is in agreement with
previous epidemiological reports [38,39] and more
recent ones suggesting that the apparent correlation of
adiponectin with HDL-C is at least partly mediated by a
mechanism whereby adiponectin increases the choles-
terol efflux from macrophages and thus preventing
atherosclerosis [40].
Expression of adiponectin receptors and adiponectin
effects
We confirmed the presence of AdipoR1 and AdipoR2 at
both mRNA and protein surface level in peripheral
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robust correlation between mRNA or surface expression
levels of the two receptors found, could indicate a syn-
chronous regulation of both genes at transcriptional and
translational level. It should be reported that a high cor-
relation between these two receptors at mRNA level has
been previously reported in peripheral monocytes from
subjects with type 2 diabetes and normal controls, as
well as in human skeletal muscle cells [5,26].
However, mRNA and surface expression levels did
not exhibit a similar pattern of expression judging
from their absolute values and their correlations.
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Figure 2 AdipoR1 and AdipoR2 (A) protein surface and (B) mRNA levels from peripheral monocytes from patients with or without
CAD. * p < 0.05.
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Page 7 of 12In fact, AdipoR1 mRNA levels were higher compared
with AdipoR2 respective ones, while the opposite was
true for the surface expression levels. In addition, Adi-
poR1 mRNA levels were inversely correlated with Mat-
suda index and AdipoR2 mRNA were positively
correlated with systolic blood pressure and triglycer-
ides, while surface expression levels of AdipoR2 were
positively correlated with Matsuda index and adiponec-
tin levels. Moreover, the presence of CAD was
associated with decreased surface expression of both
receptors. Although adiponectin receptors are
expressed in cells within atherosclerotic carotid pla-
ques [3], we did not uncover any association between
adiponectin receptors and carotid IMT values. Yet, in
CAD patients, AdipoR2 surface expression levels were
correlated with carotid bulb IMT. This finding could
represent a compensatory mechanism to decreased adi-
ponectin plasma levels.
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Page 8 of 12The aforementioned results point out that the transla-
tion and the transcription process of the adiponectin
receptors may not follow the same direction in states of
insulin resistance and atherosclerosis. The decreased
surface expression levels in combination with the
decreased adiponectin levels in CAD could contribute to
a vicious circle of decreased adiponectin action and
aggravated atherosclerotic processes.
One of the anti-inflammatory actions of the adiponec-
tin is the induction of IL-10 [6]. In our in vitro
experiments, IL-10 basal protein production was lower
in monocyte-derived macrophages from CAD patients
compared to that of nonCAD. This fact could be partly
attributed to the constant exposure to lower adiponectin
plasma levels and to basal reduced AdipoR1 and Adi-
poR2 surface levels in these cells from CAD patients.
Moreover, adiponectin-induced IL-10 secretion was
higher in macrophages from nonCAD compared to
CAD subjects, although the effect of adiponectin was
significant in both CAD and nonCAD cells.
B
0
50
100
150
200
250
300
01234567
Matsuda index
A
d
i
p
o
R
2
 
s
u
r
f
a
c
e
(
M
F
I
 
A
U
)
0
50
100
150
200
250
300
0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6
Log Adiponectin
A
d
i
p
o
R
2
 
s
u
r
f
a
c
e
(
M
F
I
 
A
U
)
A
Figure 4 Correlation of AdipoR2 surface expression levels with (A) plasma adiponectin (r = 0.359, p = 0.009), as well as with (B)
Matsuda index (r = 0.31, p = 0.029).
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Page 9 of 12Expression of human adiponectin receptors has been
examined mainly at mRNA level only by a limited num-
ber of studies which have yielded inconclusive results.
Chinetti et al reported that the expression level of Adi-
poR1 in monocytes decreases during their differentiation
into macrophages but remains higher than that of Adi-
poR2 [3]. However, only AdipoR2 was upregulated by
PPAR (peroxisome proliferators-activated receptors)
agonists which have insulin-sensitizing properties [3].
These results are in line with our findings, since we also
reported a higher level of AdipoR1 mRNA in human
monocytes and we found a positive correlation of Adi-
poR2 surface expression levels with insulin sensitivity.
Moreover, protein levels of both adiponectin receptors
in monocytes from overweight/obese diabetic patients
were reported to be decreased compared to normal
weight control subjects [5]. Expression of mRNA levels
of adiponectin receptors in human adipose tissue, in
states of insulin resistance, has been reported to be
either decreased [23-25] or increased [27]. A similar
inconsistency has been reported for muscle, where
mRNA levels are positively associated with insulin sensi-
tivity [28] or with insulin resistance [22].
Study limitations
Our study results should be interpreted with regards to
some limitations. Firstly, we did not include a control
group of normal weight subjects. Nevertheless, this does
not invalidate our findings, since the aim of the present
study was to examine adiponectin receptors with regard
only to the presence of CAD and to correlate their
expression with indices of insulin resistance and athero-
sclerosis. The later became feasible, as our subjects did
not differ in terms of BMI values but exhibited a satis-
factory variability in insulin sensitivity status, allowing
various correlations to be performed. However, it should
be noted that CAD patients presented higher values of
waist to hip ratio compared to nonCAD patients, sug-
gesting an increased prevalence of visceral adiposity
which in turn is a main determinant of adiponectin
levels and insulin sensitivity status. In addition, central
obesity is associated with increased levels of saturated
nonesterified fatty acids, which in combination with
hyperinsulinemia, may activate human monocytes to
produce proinflammatory cytokines and support the
development and propagation of the subacute, chronic
inflammatory state [41]. Interestingly, when adjusting
for Matsuda index, the difference in the surface expres-
sion levels of the adiponectin receptors between CAD
and nonCAD patients was attenuated. Moreover, Adi-
poR2 surface levels in the subgroup of CAD patients
were correlated with adiponectin, suggesting that the
decrease in AdipoR2 levels in monocytes from CAD
patients may be in relation to the decrease in insulin
sensitivity. Another limitation of this study is that our
patients were not subjected to a satisfactory wash-out
period concerning their therapeutic regimen. However,
treatment was interrupted at least 24 hours before the
measurements and adjustments for drug categories were
taken into account in our analyses. Lastly, a limitation
of our study could be the relatively small population
studied; this could imply a reduced statistical power.
Conclusions
In summary our data provide evidence that mRNA and
surface expression of the adiponectin receptors in
human monocytes seems to be subjected to different
regulatory mechanisms in states of insulin resistance
and atherosclerosis. Furthermore, the latter states are
associated with lower adiponectin plasma levels and a
decrease in surface expression of adiponectin receptors
in monocytes. This, in turn could aggravate the anti-
atherogenic action of adiponectin in CAD patients.
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